Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

European consensus conference on faecal microbiota transplantation in clinical practice.

Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group..

Gut. 2017 Jan 13. pii: gutjnl-2016-313017. doi: 10.1136/gutjnl-2016-313017. [Epub ahead of print]

2.

Emerging role of intestinal microbiota and microbial metabolites in metabolic control.

Herrema H, IJzerman RG, Nieuwdorp M.

Diabetologia. 2016 Dec 24. doi: 10.1007/s00125-016-4192-0. [Epub ahead of print]

PMID:
28013341
3.

Consensus report: faecal microbiota transfer - clinical applications and procedures.

König J, Siebenhaar A, Högenauer C, Arkkila P, Nieuwdorp M, Norén T, Ponsioen CY, Rosien U, Rossen NG, Satokari R, Stallmach A, de Vos W, Keller J, Brummer RJ.

Aliment Pharmacol Ther. 2017 Jan;45(2):222-239. doi: 10.1111/apt.13868. Review.

PMID:
27891639
4.

Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study.

Bernelot Moens SJ, Stoekenbroek RM, van der Valk FM, Verweij SL, Koelemay MJ, Verberne HJ, Nieuwdorp M, Stroes ES.

BMC Cardiovasc Disord. 2016 Nov 25;16(1):237.

5.

An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases.

Groen AK, Nieuwdorp M.

EMBO Mol Med. 2017 Jan;9(1):1-3. doi: 10.15252/emmm.201607035. No abstract available.

6.

Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion.

Jakulj L, van Dijk TH, de Boer JF, Kootte RS, Schonewille M, Paalvast Y, Boer T, Bloks VW, Boverhof R, Nieuwdorp M, Beuers UH, Stroes ES, Groen AK.

Cell Metab. 2016 Dec 13;24(6):783-794. doi: 10.1016/j.cmet.2016.10.001.

PMID:
27818259
7.

Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk.

Koopen AM, Groen AK, Nieuwdorp M.

Curr Opin Lipidol. 2016 Dec;27(6):615-622.

PMID:
27676197
8.

Causality of small and large intestinal microbiota in weight regulation and insulin resistance.

Scheithauer TP, Dallinga-Thie GM, de Vos WM, Nieuwdorp M, van Raalte DH.

Mol Metab. 2016 Jun 10;5(9):759-70. doi: 10.1016/j.molmet.2016.06.002.

9.

Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.

Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS, Nieuwdorp M, Groen AK, Olde Damink SW, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CH, Blaak EE.

Cell Metab. 2016 Aug 9;24(2):341. doi: 10.1016/j.cmet.2016.07.008. No abstract available.

PMID:
27508877
10.

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES.

Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838.

PMID:
27496857
11.

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Nieuwdorp M, Groen AK, Cahen DL, van Raalte DH.

Diabetes Obes Metab. 2016 Dec;18(12):1217-1225. doi: 10.1111/dom.12748.

12.

Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial.

Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS, Nieuwdorp M, Groen AK, Olde Damink SW, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CH, Blaak EE.

Cell Metab. 2016 Jul 12;24(1):63-74. doi: 10.1016/j.cmet.2016.06.016.

PMID:
27411009
13.

Effective Electroconvulsive Therapy in a Patient With Psychotic Depression With Active Cushing Disease.

van Rooijen G, Denys D, Fliers E, Nieuwdorp M.

J ECT. 2016 Sep;32(3):e20-1. doi: 10.1097/YCT.0000000000000339. No abstract available.

PMID:
27379791
14.

Durable coexistence of donor and recipient strains after fecal microbiota transplantation.

Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P.

Science. 2016 Apr 29;352(6285):586-9. doi: 10.1126/science.aad8852.

PMID:
27126044
15.

Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans.

Ter Horst KW, Gilijamse PW, Ackermans MT, Soeters MR, Nieuwdorp M, Romijn JA, Serlie MJ.

Metabolism. 2016 May;65(5):757-63. doi: 10.1016/j.metabol.2016.02.010.

PMID:
27085782
16.

Sexual Dimorphism in Hepatic, Adipose Tissue, and Peripheral Tissue Insulin Sensitivity in Obese Humans.

Ter Horst KW, Gilijamse PW, de Weijer BA, Kilicarslan M, Ackermans MT, Nederveen AJ, Nieuwdorp M, Romijn JA, Serlie MJ.

Front Endocrinol (Lausanne). 2015 Nov 26;6:182. doi: 10.3389/fendo.2015.00182.

17.

Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.

Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S69-73. doi: 10.1097/MCG.0000000000000420.

PMID:
26447969
18.

Gut Microbiota and Energy Expenditure in Health and Obesity.

Bakker GJ, Zhao J, Herrema H, Nieuwdorp M.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S13-9. doi: 10.1097/MCG.0000000000000363. Review.

PMID:
26447957
19.

Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study.

Smits LP, Coolen BF, Panno MD, Runge JH, Nijhof WH, Verheij J, Nieuwdorp M, Stoker J, Beuers UH, Nederveen AJ, Stroes ES.

Radiology. 2016 Mar;278(3):782-91. doi: 10.1148/radiol.2015150952.

PMID:
26348104
20.

Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?

Melgar S, Nieuwdorp M.

Gastroenterology. 2015 Oct;149(4):848-50. doi: 10.1053/j.gastro.2015.08.039. No abstract available.

PMID:
26306767
Items per page

Supplemental Content

Loading ...
Support Center